30938 Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices 

qualified candidates to apply to be 

considered for appointment to the 

Committee. 

DATES: Applicable: July 2, 2018. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Ken Sandler, Office of Federal HighPerformance Buildings, GSA, 202–219– 

1121. 

SUPPLEMENTARY INFORMATION: 

Background 

The Administrator of the GSA 

established the Green Building Advisory 

Committee (hereafter, ‘‘the Committee’’) 

on June 20, 2011 (76 FR 118) pursuant 

to Section 494 of the Energy 

Independence and Security Act of 2007 

(42 U.S.C. 17123, or EISA), in 

accordance with the provisions of the 

Federal Advisory Committee Act 

(FACA), as amended (5 U.S.C. App. 2). 

Under this authority, the Committee 

advises GSA on how the Office of 

Federal High-Performance Buildings can 

most effectively accomplish its mission. 

Extensive information about the 

Committee, including current members, 

is available on GSA’s website at http:// 

www.gsa.gov/gbac. 

Membership requirements: The EISA 

statute authorizes the Committee and 

identifies the categories of members to 

be included. EISA names 10 federal 

agencies and offices to be represented 

on the Committee, and GSA works 

directly with these agencies to identify 

their qualified representatives. This 

notice is focused exclusively on nonfederal members. EISA provides that, in 

addition to its required federal 

members, the Committee shall include 

‘‘other relevant agencies and entities, as 

determined by the Federal Director.’’ 

These are to include at least one 

representative of each of the following 

categories: 

‘‘(i) State and local governmental 

green building programs; 

(ii) Independent green building 

associations or councils; 

(iii) Building experts, including 

architects, material suppliers, and 

construction contractors; 

(iv) Security advisors focusing on 

national security needs, natural 

disasters, and other dire emergency 

situations; 

(v) Public transportation industry 

experts; and 

(vi) Environmental health experts, 

including those with experience in 

children’s health.’’ 

EISA further specifies: ‘‘the total 

number of non-federal members on the 

Committee at any time shall not exceed 

15.’’ 

Member responsibilities: Approved 

Committee members will be appointed 

to terms of either 2 or 4 years with the 

possibility of membership renewals as 

appropriate. Membership is limited to 

the specific individuals appointed and 

is non-transferrable. Members are 

expected to attend all meetings in 

person, review all Committee materials, 

and actively provide their advice and 

input on topics covered by the 

Committee. Committee members will 

not receive compensation or travel 

reimbursements from the Government 

except where need has been 

demonstrated and funds are available. 

Request for membership nominations: 

This notice provides an opportunity for 

individuals to present their 

qualifications and apply for an open 

seat on the Committee. GSA will ask 

Committee members whose terms are 

expiring to re-apply if they are 

interested in continuing to serve on the 

Committee. GSA will review all 

applications and determine which 

candidates are likely to add the most 

value to the Committee based on the 

criteria outlined in this notice. 

At a minimum, prospective members 

must have: 

—At least 5 years of high-performance 

building experience, which may 

include a combination of projectbased, research and policy 

experience. 

—Academic degrees, certifications and/ 

or training demonstrating highperformance building and related 

sustainability and real estate 

expertise. 

—Knowledge of federal sustainability 

and energy laws and programs. 

—Proven ability to work effectively in a 

collaborative, multi-disciplinary 

environment and add value to the 

work of a committee. 

—Qualifications appropriate to specific 

statutory requirements (listed above). 

No person who is a federallyregistered lobbyist may serve on the 

Committee, in accordance with the 

Presidential Memorandum ‘‘Lobbyists 

on Agency Boards and Commissions’’ 

(June 18, 2010). 

Nomination process for Advisory 

Committee appointment: There is no 

prescribed format for the nomination. 

Individuals may nominate themselves 

or others. A nomination package shall 

include the following information for 

each nominee: (1) A letter of nomination 

stating the name and organizational 

affiliation(s) of the nominee, 

membership capacity he/she will serve 

(per statutory categories above), 

nominee’s field(s) of expertise, and 

description of interest and 

qualifications; (2) A professional resume 

or CV; and (3) Complete contact 

information including name, return 

address, email address, and daytime 

telephone number of the nominee and 

nominator. GSA will consider 

nominations of all qualified individuals 

to ensure that the Committee includes 

the areas of high-performance building 

subject matter expertise needed. GSA 

reserves the right to choose Committee 

members based on qualifications, 

experience, Committee balance, 

statutory requirements and all other 

factors deemed critical to the success of 

the Committee. Candidates may be 

asked to provide detailed financial 

information to permit evaluation of 

potential conflicts of interest that could 

impede their work on the Committee, in 

accordance with the requirements of 

FACA. All nominations must be 

submitted in sufficient time to be 

received by 5 p.m., Eastern Daylight 

Time (EDT), on Thursday, July 26, 2018, 

and be addressed to ken.sandler@

gsa.gov. 

Dated: June 27, 2018. 

Kevin Kampschroer, 

Federal Director, Office of Federal HighPerformance Buildings, Office of Governmentwide Policy. 

[FR Doc. 2018–14200 Filed 6–29–18; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–18–18CV] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

In accordance with the Paperwork 

Reduction Act of 1995, the Centers for 

Disease Control and Prevention (CDC) 

has submitted the information 

collection request titled Rapid Response 

Suicide Investigation Data Collection to 

the Office of Management and Budget 

(OMB) for review and approval. CDC 

previously published a ‘‘Proposed Data 

Collection Submitted for Public 

Comment and Recommendations’’ 

notice on November 9, 2017 to obtain 

comments from the public and affected 

agencies. CDC did not receive comments 

related to the previous notice. This 

notice serves to allow an additional 30 

days for public and affected agency 

comments. 

CDC will accept all comments for this 

proposed information collection project. 

The Office of Management and Budget 

is particularly interested in comments 

that: 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices 30939 

(a) Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

(b) Evaluate the accuracy of the 

agencies estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; 

(d) Minimize the burden of the 

collection of information on those who 

are to respond, including, through the 

use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and 

(e) Assess information collection 

costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Direct 

written comments and/or suggestions 

regarding the items contained in this 

notice to the Attention: CDC Desk 

Officer, Office of Management and 

Budget, 725 17th Street NW, 

Washington, DC 20503 or by fax to (202) 

395–5806. Provide written comments 

within 30 days of notice publication. 

Proposed Project 

Rapid Response Suicide Investigation 

Data Collection—New—National Center 

for Injury Prevention and Control 

(NCIPC), Centers for Disease Control 

and Prevention (CDC) 

Background and Brief Description 

CDC is frequently called upon to 

respond to urgent requests from one or 

more external partners (e.g., local, state, 

territory, and tribal health authorities; 

other federal agencies; local and state 

leaders; schools; or other partner 

organizations) to conduct investigations 

of suicide. Supporting rapid 

investigations to inform the 

implementation of effective suicide 

prevention strategies is one of the most 

important ways CDC can serve to 

protect and promote the health of the 

public. Prior to this request, CDC had 

collected data for a suicide investigation 

via the OMB-approved Emergency 

Epidemic Investigations (EEI) ICR (OMB 

No. 0920–1011; expiration 3/31/2020), 

which supported data collections for 

Epi-Aid investigations. However, this 

mechanism is no longer available for 

rapid suicide responses due to the 

narrowing in scope of that generic. CDC 

requests approval for a 3-year period for 

this Generic Information Collection 

Request to rapidly respond to urgent 

requests for CDC assistance to 

investigate an apparent and 

unexplained potential cluster or 

increase in suicidal behavior. Rapid 

Response Suicide Investigation Data 

Collections are specifically designed to 

inform the implementation of 

prevention strategies in a state, county, 

community, or vulnerable population 

where a possible suicide cluster or 

increasing trend has been observed. 

This generic clearance will not be used 

to conduct research studies or to collect 

data designed to draw conclusions 

about the United States or areas beyond 

the defined geographic location or 

vulnerable population that is the focus 

of the investigation. 

These public health data are used by 

external partners (e.g., local, state, 

territory, and tribal health authorities; 

other federal agencies; local and state 

leaders; schools; or other partner 

organizations) to identify, prioritize, and 

implement strategies to prevent suicidal 

behavior and suicide. Rapid Response 

Suicide Investigation Data Collections 

methods will vary and depend on the 

unique circumstances of the urgent and 

rapid response and objectives 

determined by CDC. Investigations may 

use descriptive and/or cohort- or casecontrol designs. Data collection modes 

may include: (a) Archival record 

abstraction; (b) face-to-face interview; 

(c) telephone interview; (d) web-based 

questionnaire; (e) self-administered 

questionnaire; and (f) focus groups. 

Multiple data collection designs and 

modes are likely to be employed in a 

single investigation. The subpopulation 

will vary and depend on the unique 

circumstances of the Rapid Response 

Suicide Investigation Data Collections. 

Requests for assistance may include a 

state, county, community, or vulnerable 

population. Suicide rates are increasing 

across age-groups and vulnerable 

populations, include, but are not limited 

to, youth, middle-aged adults, active 

duty service personnel, veterans, and 

American Indian/Alaska Native 

communities. Investigations likely will 

often require collection of information 

from 10 or more respondents. The data 

analytic approach for the Rapid 

Response Suicide Investigation Data 

Collection will vary and depend on the 

objectives and methods of the 

investigation. Multiple analytical 

strategies are likely to be employed in 

a single investigation. This may include 

descriptive analyses, logistic regression, 

and temporal and spatial cluster 

analyses. The goal of the analyses is to 

inform suicide prevention strategies by 

understanding (a) significant increases 

in fatal or nonfatal suicidal behavior; (b) 

the risk factors associated with trends of 

fatal or nonfatal suicidal behavior; (c) 

the groups most affected (e.g., gender, 

age, location in community or state); 

and (d) current risk and protective 

factors and prevention opportunities. 

The total estimated annualized burden 

for this collection is 1,000 hours. The 

only cost to respondents will be time 

spent responding to the surveys. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Rapid Response Suicide Investigation Data 

Collection Participants.

Rapid Response Suicide Investigation Data 

Collection Instruments.

2,000 1 30/60 


daltland on DSKBBV9HB2PROD with NOTICES
30940 Federal Register / Vol. 83, No. 127 / Monday, July 2, 2018 / Notices 

Jeffrey M. Zirger, 

Acting Chief, Office of Scientific Integrity, 

Office of the Associate Director for Science, 

Office of the Director, Centers for Disease 

Control and Prevention. 

[FR Doc. 2018–14172 Filed 6–29–18; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2018–N–2027] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Survey of Current 

Manufacturing Practices for the 

Cosmetics Industry 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA, Agency, or we) is 

announcing an opportunity for public 

comment on the proposed collection of 

certain information by the Agency. 

Under the Paperwork Reduction Act of 

1995 (PRA), Federal Agencies are 

required to publish notice in the 

Federal Register concerning each 

proposed collection of information and 

to allow 60 days for public comment in 

response to the notice. This notice 

solicits comments on a new information 

collection: A survey of the cosmetics 

industry on their current manufacturing 

practices. 

DATES: Submit either electronic or 

written comments on the collection of 

information by August 31, 2018. 

ADDRESSES: You may submit comments 

as follows. Please note that late, 

untimely filed comments will not be 

considered. Electronic comments must 

be submitted on or before August 31, 

2018. The https://www.regulations.gov 

electronic filing system will accept 

comments until midnight Eastern Time 

at the end of August 31, 2018. 

Comments received by mail/hand 

delivery/courier (for written/paper 

submissions) will be considered timely 

if they are postmarked or the delivery 

service acceptance receipt is on or 

before that date. 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2018–N–2027 for ‘‘Agency Information 

Collection Activities; Proposed 

Collection; Comment Request; Survey of 

Current Manufacturing Practices for the 

Cosmetics Industry.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 

9 a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov/ 

fdsys/pkg/FR-2015-09-18/pdf/2015- 

23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: Ila 

S. Mizrachi, Office of Operations, Food 

and Drug Administration, Three White 

Flint North, 10A–12M, 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–7726, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes Agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

Agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 


daltland on DSKBBV9HB2PROD with NOTICES